OnCo
Start here·Rankings·All cancers

Cancers with most trials per approved product

JSON

Cancers with at least ten trials, excluding umbrella records that other cancers name as their parent, ordered by trials divided by approved products, with cancers that have no approved product first. Top 50 of 59 cancers with a value; ties are broken by name. 3,560 of 3,571 trials name at least one cancer (100%).

#CancerTrials per approved product
1Metastatic cancer (cancer that has spread)no approved product
2Oesophageal squamous cell carcinomano approved product
3HPV-positive oropharyngeal cancerno approved product
4Metastatic pancreatic ductal adenocarcinoma31
5Muscle-invasive and advanced bladder cancer24.5
6Localised prostate cancer, high and very high risk12
7Rectal cancer12
8Non-muscle-invasive bladder cancer11.3
9Platinum-resistant ovarian cancer10.3
10HER2-positive gastric cancer10
11Recurrent or metastatic head and neck squamous cell carcinoma9.5
12EGFR-mutated non-small-cell lung cancer9.4
13Relapsed or refractory chronic lymphocytic leukaemia9
14Resectable stage I to III non-small-cell lung cancer9
15Relapsed or refractory multiple myeloma8.1
16KRAS G12C-mutant non-small-cell lung cancer8
17Uveal melanoma8
18Metastatic castration-resistant prostate cancer7.4
19Recurrent or metastatic cervical cancer7.3
20Oesophageal and junctional adenocarcinoma7
21Unresectable stage III non-small-cell lung cancer7
22Advanced or recurrent endometrial cancer6.7
23KRAS G12C-mutant colorectal cancer6.5
24Follicular lymphoma6.4
25Metastatic triple-negative breast cancer6.3
26HER2-mutant non-small-cell lung cancer6.3
27Platinum-sensitive ovarian cancer6
28Advanced hepatocellular carcinoma (BCLC C)5.8
29Early HER2-positive breast cancer5.5
30Extensive-stage small-cell lung cancer5.4
31Chronic lymphocytic leukaemia, first treatment5.3
32Mantle cell lymphoma5.2
33Intermediate hepatocellular carcinoma (BCLC B)5
34Mismatch-repair deficient (MSI-high) colorectal cancer4.5
35PD-L1-high non-small-cell lung cancer without a driver mutation4.5
36Advanced melanoma (unresectable stage III and stage IV)4.1
37Clear cell renal cell carcinoma4
38High-risk early HR-positive breast cancer4
39Acute myeloid leukaemia in older or unfit patients3.7
40Merkel cell carcinoma3.7
41High-grade serous ovarian cancer3.5
42Early triple-negative breast cancer3.3
43Polycythaemia vera (PV)3.3
44Primary myelofibrosis3.3
45Brain metastases (secondary brain tumours)3
46Metastatic hormone-sensitive prostate cancer3
47Recurrent and metastatic nasopharyngeal carcinoma3
48Osteosarcoma2.8
49MET exon 14 and MET-amplified non-small-cell lung cancer2.7
50Intrahepatic cholangiocarcinoma2.5

9 more cancers have a value below the top 50; the full list of cancers is at /cancers/.

How this is counted

For each cancer with ten or more trial records, divides the trial count by the number of products with status approved that list the cancer. Cancers with no approved product cannot be divided and are placed first, ordered by their trial count. The ten-trial floor keeps a cancer with one trial and no product from topping the table, and umbrella records (any cancer that another cancer record names as its parent) are left out because their approvals sit on the subtypes.

Coverage. 3,560 of 3,571 trials name at least one cancer (100%). Rows with a value of zero are not listed. Nothing is weighted, imputed or averaged; the ordering is by the number shown, then by name.

Machine-readable copy: /rankings/cancers-least-served/data.json. Registry: src/lib/rankings.ts.

Other rankings